J.P. Morgan analyst Anne Samuel maintained a Hold rating on Omnicell (NASDAQ:OMCL) on Tuesday, setting a price target of $148, which is approximately 18.48% below the present share price of $181.55.
Samuel expects Omnicell to post earnings per share (EPS) of $0.67 for the fourth quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Moderate Buy rating of shares in Omnicell, with an average price target of $183.67.
The analysts price targets range from a high of $211 to a low of $148.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $296.4 million and a net profit of $29.39 million. The company's market cap is $7.98 billion.
According to TipRanks.com, J.P. Morgan analyst Anne Samuel is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 50.2% and a 60.00% success rate.
Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence; platform and interoperability; central pharmacy dispensing; medication adherence; population health; and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Mountain View, CA.